OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) Director David Pelizzon sold 4,000 shares of OrthoPediatrics stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00. Following the sale, the director owned 6,897,764 shares of the company’s stock, valued at approximately $177,617,423. The trade was a 0.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
OrthoPediatrics Stock Performance
Shares of NASDAQ:KIDS traded down $0.47 during midday trading on Wednesday, reaching $24.03. The company’s stock had a trading volume of 169,608 shares, compared to its average volume of 171,545. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average of $21.11 and a 200 day moving average of $18.53. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The firm has a market capitalization of $627.42 million, a PE ratio of -14.30 and a beta of 0.98.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. On average, equities analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.
Institutional Trading of OrthoPediatrics
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on KIDS shares. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, BTIG Research raised their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.44.
Read Our Latest Report on OrthoPediatrics
OrthoPediatrics Company Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Articles
- Five stocks we like better than OrthoPediatrics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
